Why mRNA Delivery is Shaping the Future of Genome Editing

A first step in a new direction

September 23, 2026 by Aldevron

For years, the dominant approach to delivering CRISPR systems into cells has been direct delivery of Cas9 protein as part of a ribonucleoprotein (RNP) complex. This method offers rapid editing and minimal persistence, making it ideal for many ex vivo workflows. But as genome editing moves deeper into therapeutic applications and scales for clinical use, the industry is beginning to embrace a new paradigm: mRNA delivery of gene editing tools.

Why mRNA Delivery Is Gaining Traction
mRNA delivery offers several advantages that align with the needs of modern genome editing programs:

• Transient expression without integration risk
• Manufacturing scalability
• High-fidelity editing (high on-target and low off-target)
• Compatibility with advanced delivery systems
• Reduced Immunogenicity

In addition, producing mRNA at GMP scale is simpler and more predictable than purifying large, complex proteins. This makes mRNA a natural fit for workflows that need to move from research to clinical development quickly and have therapeutic applications in mind. mRNA integrates seamlessly with lipid nanoparticle (LNP) platforms, which are already proven in mRNA vaccines and increasingly used for in vivo gene editing. Chemical modifications like N1-Methylpseudouridine and advanced capping technologies minimize innate immune activation, improving safety and efficiency.

Cas9 mRNA: The First Step in a Bigger Trend
Cas9 remains the workhorse of CRISPR-based editing, and mRNA delivery is now emerging as a powerful alternative to RNPs. High-fidelity variants like  Spy Fi™ further reduce off-target effects, supporting precision genome engineering in sensitive cell types such as T cells. But the future will move beyond Cas9 into more bespoke and targeted editors.

Looking Ahead: Prime and Base Editors
The shift to mRNA delivery isn’t just about Cas9. Next-generation editors—such as Prime Editors and Base Editors—are even more complex than Cas9, making direct protein delivery increasingly impractical. mRNA offers a scalable, transient, and controllable way to express these sophisticated tools, paving the way for:

• Multiplexed editing strategies
• In vivo therapeutic applications
• Faster transitions from discovery to clinical trials

As these technologies mature, mRNA delivery will likely become the standard for genome editing tools, enabling safer, more efficient workflows across research and medicine.

Regulatory Outlook: A Recipe-Based Approach
One emerging idea in regulatory circles is that mRNA-based gene editing tools could be evaluated as a platform rather than on a case-by-case basis. Instead of requiring separate approvals for every guide RNA or target, agencies may treat the mRNA editor as a validated “recipe.” Once the core mRNA construct—such as a Prime Editor—is approved, subsequent applications using different guides could leverage that approval, streamlining development and accelerating therapeutic timelines.

Implications for Therapeutic Development
For cell therapy and in vivo applications, mRNA delivery aligns with GMP manufacturing requirements and regulatory expectations. It supports predictable, reproducible processes—critical for programs moving toward IND submissions and commercialization.

Aldevron’s Role in This Evolution
Aldevron is helping lead this transition with Cas9 mRNA formats optimized for high efficiency and low toxicity, available in both wild type and  Spy Fi™ high-fidelity variants. Through our partnership with IDT and our proven track record from research-grade to cGMP manufacturing, we provide continuity and technical expertise to accelerate your genome editing program.

If you’re ready to explore mRNA delivery for your next project, learn more on how how Aldevron’s Cas9 mRNA solutions—and future-ready capabilities—can help you stay ahead in genome editing.

• Check out our Cas9 mRNA solutions
• Have questions on this topic? Contact Us
• Have an idea for a topic? Let us know!

Subscribe to our blog